Adults with kidney cancer invited to be in an immunotherapy research study

IRB/UVA Tracking #
Principal Investigator
Robert Dreicer
Jennifer Drake
Contact Email
Contact Phone
Official Trial Title
A Phase 3 RandOmized Study Comparing PERioperative Nivolumab vs. Observation in Patients with Renal Cell Carcinoma Undergoing Nephrectomy (PROSPER RCC)
Study Description

The University of Virginia is conducting a clinical research study for adults ages 18 and over, who have kidney cancer. The purpose of this study is to compare any good and bad effects of using nivolumab (also known as OPDIVO®), before and after the kidney cancer surgery to using the usual approach of surgically removing the kidney cancer followed by standard post-operative follow-up and monitoring. There are two groups in this study. Group 1 will receive nivolumab followed by surgery, followed by nivolumab. Group 2 will have surgery followed by close observation, which is the usual approach to treatment.

The length of participation is dependent on which group you are in. If you are in Group 1, you will receive 1 dose of the nivolumab prior to surgery. Then, starting at least 4 weeks after your surgery, you will receive nivolumab once every 4 weeks for 9 months. After you finish taking nivolumab, you will then be monitored for up to 10 years. If you are in Group 2 you will have the surgery and then by monitored for up to 10 years.

Study-related procedures that are being done beyond your standard of care will be provided at no cost to your or your insurance.

Additional information can be found here:


No Compensation